
Opinion|Videos|January 19, 2026
Addressing Access Barriers and Formulary Restrictions
Panelists discuss how addressing payer restrictions and leveraging data-driven advocacy are essential for timely access to care.
Advertisement
Episodes in this series

Panelists discuss how payer-imposed step edits and prior authorizations continue to delay patient access to needed treatments. These administrative barriers often exacerbate symptom relapse and caregiver strain.
Panelists discuss how providers rely on real-world evidence and outcomes data to justify coverage approvals and ensure continuity of care.
Panelists discuss how policy reform and closer collaboration between clinicians, payers, and advocacy groups can streamline access and reduce inequities.
Advertisement
Related to this article

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.

Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.

Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
3
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

